144 related articles for article (PubMed ID: 28179005)
1. Clinical impact of extensive molecular profiling in advanced cancer patients.
Cousin S; Grellety T; Toulmonde M; Auzanneau C; Khalifa E; Laizet Y; Tran K; Le Moulec S; Floquet A; Garbay D; Robert J; Hostein I; Soubeyran I; Italiano A
J Hematol Oncol; 2017 Feb; 10(1):45. PubMed ID: 28179005
[TBL] [Abstract][Full Text] [Related]
2. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
3. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
4. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
7. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
[TBL] [Abstract][Full Text] [Related]
8. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
9. Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.
Lane BR; Bissonnette J; Waldherr T; Ritz-Holland D; Chesla D; Cottingham SL; Alberta S; Liu C; Thompson AB; Graveel C; MacKeigan JP; Noyes SL; Smith J; Lakhani N; Steensma MR;
J Mol Diagn; 2015 Nov; 17(6):695-704. PubMed ID: 26331835
[TBL] [Abstract][Full Text] [Related]
10. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
Postel-Vinay S; Boursin Y; Massard C; Hollebecque A; Ileana E; Chiron M; Jung J; Lee JS; Balogh Z; Adam J; Vielh P; Angevin E; Lacroix L; Soria JC
Ann Oncol; 2016 Feb; 27(2):344-52. PubMed ID: 26598538
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
[TBL] [Abstract][Full Text] [Related]
12. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
13. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
[TBL] [Abstract][Full Text] [Related]
14. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
[TBL] [Abstract][Full Text] [Related]
15. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
16. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
17. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M; Fleitas T; Llorca-Cardeñosa MJ; Mongort C; Alonso E; Navarro S; Burgues O; Vivancos A; Cejalvo JM; Perez-Fidalgo JA; Roselló S; Ribas G; Cervantes A
Oncotarget; 2016 Apr; 7(16):22543-55. PubMed ID: 26968814
[TBL] [Abstract][Full Text] [Related]
18. Identifying Genomic Alterations in Patients With Stage IV Breast Cancer Using MammaSeq: An International Collaborative Study.
Shah OS; Soran A; Sahin M; Knapick BA; Ugras S; Celik E; Lucas PC; Lee AV
Clin Breast Cancer; 2021 Jun; 21(3):210-217. PubMed ID: 33191115
[TBL] [Abstract][Full Text] [Related]
19. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Takenaka M; Saito M; Iwakawa R; Yanaihara N; Saito M; Kato M; Ichikawa H; Shibata T; Yokota J; Okamoto A; Kohno T
Int J Oncol; 2015; 46(6):2389-98. PubMed ID: 25846456
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
